The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
about
Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancerEmerging therapeutic biomarkers in endometrial cancerThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memoryPrognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen ModelSafety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.Wilms' Tumour gene 1 (WT1) as an immunotherapeutic targetImmune therapy for ovarian cancer: promise and pitfalls.Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysisImiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.Endometrial cancer evolution: new molecular-biologic types and hormonal-metabolic shifts.
P2860
Q26861293-1C93B1CB-1FC7-4EA7-973A-101941581D38Q26865904-FE4DF305-EF3A-4539-9136-C2867A1DF125Q33815087-692DEB2A-9472-45B8-9CDB-D12CCB2F6663Q34760326-E68389BC-6CDE-4DED-B535-2512F090AACBQ35053993-F77F26A8-40EB-48EA-9315-AD5D4EA4738EQ35677893-2CE47DB0-F0DA-4429-84AB-99F8DD18EAC9Q35799297-84420606-3283-4AFF-9DBE-2BBB54EE2170Q35818203-FB4E36A7-D8B3-4362-ADD3-7AC1BAC991A9Q36199847-43E0E000-D6FA-4347-BB1A-8F0F043C04A0Q37184585-DADA28B3-0B1D-437E-9CD2-E05910BAAD71Q37675627-0223A527-B347-441C-AE70-6D61D4F0B42CQ37704104-EEC96838-4C47-40D6-AF07-46CFF9545EACQ37873928-B0943C52-4CA2-4E1F-83A4-218D965732F4Q39777761-A1C0C5DF-8A70-4FD6-9F33-64347677FDD6Q41815158-70AEC93A-E29F-4A7A-B4B4-17CD4ABC7B1EQ47424270-A730F9DE-C20E-45F7-8BDB-94B3B7C498A0
P2860
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
The emergence of immunomodulat ...... rtunities for the next decade.
@ast
The emergence of immunomodulat ...... rtunities for the next decade.
@en
type
label
The emergence of immunomodulat ...... rtunities for the next decade.
@ast
The emergence of immunomodulat ...... rtunities for the next decade.
@en
prefLabel
The emergence of immunomodulat ...... rtunities for the next decade.
@ast
The emergence of immunomodulat ...... rtunities for the next decade.
@en
P2093
P2860
P1433
P1476
The emergence of immunomodulat ...... ortunities for the next decade
@en
P2093
Andrea Facciabene
Daniel J Powell
John B Liao
Jonathan S Berek
Lana E Kandalaft
Nathan Singh
P2860
P304
P356
10.1016/J.YGYNO.2009.11.001
P407
P577
2009-12-02T00:00:00Z